Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma 2Immunoblastic Lymphadenopathy 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Mycosis Fungoides 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Prolymphocytic, T-Cell 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 12Biopsy 10Specimen Handling 9Whole-Body Irradiation 7Magnetic Resonance Spectroscopy 7pembrolizumab 6Peripheral Blood Stem Cell Transplantation 6Melphalan 6Etoposide 6fludarabine 5duvelisib 5Brentuximab Vedotin 5ruxolitinib 4fludarabine phosphate 4Vincristine 4Prednisone 4Doxorubicin 4Cytarabine 410-propargyl-10-deazaaminopterin 4romidepsin 3X-Rays 3Mycophenolic Acid 3Immunoglobulin G 3Granulocyte Colony-Stimulating Factor 3Gemcitabine 3Disulfides 3Carmustine 3venetoclax 2tazemetostat 2sodium-iodide symporter 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, T-Cell × romidepsin × 1 year × Clear all
NCT02783625 2026-04-24

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
114 enrolled
Lymphoid

Lymphoma, Lymphoma, T-Cell

NCT03278782 2026-01-09

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
39 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT01908777 2025-10-09

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
47 enrolled
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡